The Hormone Related Malignancies (HRM) Program members study cancers of the reproductive tract and breast, and research the role of hormones in establishing and maintaining these cancers, the progression of these cancers to hormone-independent states, and mechanisms contributing to metastasis. The goal is to prevent, diagnose, and treat these cancers more effectively. Members are engaged in translating their knowledge of these processes into biomarkers and therapeutic targets for cancer patients through clinical trials. Novel technologies and approaches developed by the program to address these areas include 1) animal models to study epithelial to mesenchymal transition (EMT), cancer stem cells, apoptosis, and the microenvironment's role in metastasis;and 2) functional genomic and high throughput screens to identify new drugs targeting novel pathways in HRM-related cancers. The HRM Program includes highly interactive basic researchers and clinicians that promote the translational nature of the research conducted. HRM has two focus groups: 1) Women's Cancers, and 2) Prostate Cancer. In the prior funding period HRM made several major contributions to the field including: 1) Demonstration that screening does not reduce 10-year prostate cancer mortality, shedding light on the controversy surrounding prostate cancer screening {New Eng J of Med);2) The identification of Six1 as a critical tumor and metastasis promoting factor (J Clin Invest), and development of a program to identify small molecules of the Six1/Eya complex as an anti-breast cancer strategy;3) Discovery that the pro-inflammatory involution microenvironment stimulates pregnancy-associated breast cancer, leading to a clinical trial of fish oil and celecoxib in women with newly diagnosed breast cancer;and 4) The contribution of new recommendations for using 5 alpha-reductase inhibitors for prostate cancer prevention based on pathological characteristics observed in tumors of the Prostate Cancer Prevention Trial (New Eng J of Med, J Natl Cancer Inst, and Cancer Prev Res). HRM has 29 full members in 9 Departments and 3 schools at UCD and Colorado State University (CSU). HRM researchers currently hold $3.8M direct costs in NCI grants and $7.4M direct costs in other cancer relevant grants. Since 2005, per capita cancer research funding has increased by 56% from $247K to $385K. HRM produced 435 cancer-related publications from 2005-2010. Of these, 115 (26%) were interprogrammatic; 63 (15%) were intra-programmatic;and 52 (12%) were both inter- and intra-programmatic. Thus, 230 (53%) of the total cancer-related publications by members of this program were collaborative.

Public Health Relevance

The Hormone Related Malignancies Program (HRM) fosters cancer-focused inter-disciplinary research among basic scientists, clinical researchers and epidemiologists who study cancers of the reproductive tract and breast The goal is to prevent, diagnose, and treat these cancers more effectively through the translation of lab-based discoveries into therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-25
Application #
8567525
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$84,148
Indirect Cost
$27,538
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Gillen, Austin E; Yamamoto, Tomomi M; Kline, Enos et al. (2016) Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics 17:338
Justice, Cristina M; Bishop, Kevin; Carrington, Blake et al. (2016) Evaluation of IRX Genes and Conserved Noncoding Elements in a Region on 5p13.3 Linked to Families with Familial Idiopathic Scoliosis and Kyphosis. G3 (Bethesda) 6:1707-12
Eckwahl, Matthew J; Arnion, Helene; Kharytonchyk, Siarhei et al. (2016) Analysis of the human immunodeficiency virus-1 RNA packageome. RNA 22:1228-38
Iguchi, Nao; Malykhina, Anna P; Wilcox, Duncan T (2016) Inhibition of HIF Reduces Bladder Hypertrophy and Improves Bladder Function in Murine Model of Partial Bladder Outlet Obstruction. J Urol 195:1250-6
Seedorf, Gregory; Metoxen, Alexander J; Rock, Robert et al. (2016) Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am J Physiol Lung Cell Mol Physiol 310:L1098-110
Agarwal, Neeraj; Dancik, Garrett M; Goodspeed, Andrew et al. (2016) GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res 76:5175-85
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322
Munson, Daniel J; Egelston, Colt A; Chiotti, Kami E et al. (2016) Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A 113:8272-7
Scott, Aaron J; Lieu, Christopher H; Messersmith, Wells A (2016) Therapeutic Approaches to RAS Mutation. Cancer J 22:165-74

Showing the most recent 10 out of 1302 publications